Investigation on Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses of a Long-acting GLP-1 Analogue (Semaglutide) in an Oral Formulation in Healthy Male Subjects
Phase of Trial: Phase I
Latest Information Update: 16 Jun 2014
At a glance
- Drugs Semaglutide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Novo Nordisk
- 25 Apr 2014 Trial status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 21 Jan 2014 Status changed from recruiting to active, no longer recruiting according to ClinicalTrials.gov record.
- 05 Jun 2013 New trial record